Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol. 2004;5:430-442.
Anderson KC. Progress and Paradigms in Multiple Myeloma. Clin Canc Res. 2016;22:5419-5427.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Multiple myeloma. V5.2018. https://www.nccn.org/.
Chari A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics: Targets & Therapy. 2010;4:273–287.
Shi Q, Chen L. Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation. J Immunol Res. 2017. doi: 10.1155/2017/9130608. [Epub ahead of print].
Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621-631.
Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841-1849.
Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618-621
Velcade® [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2017.
Kyprolis® [package insert]. Thousand Oaks, CA: Onyx Pharmaceuticals, Inc.; 2018.
Ninlaro® [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2016.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548
Greipp PR, San Miguel J, Durie BG, et al. International Staging System for Multiple Myeloma. J Clin Oncol. 2005;23:3412-3420.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863-2869.
Chng WJ, Dispenzieri A, Chim C-S, et al. IMWG consensus on risk stratification in multiple myeloma Leukemia. 2014;28:269-277.
Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519-527.
Attal M, Lauwers-Cances , Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311-1320.
Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068-2074.
Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. 2015;126:2179-2185.
McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279-3289.
Sonneveld P, Avet-Loiseah H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955-2562.
Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946-2955.
Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patientsLeukemia. 2013;28:690-693.
Darzalex® [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2017.
Mateos B-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518-528.
Kurtin SE, Bilotti E. Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. J Adv Pract Oncol. 2013;4:307-321.
Raje NS, Yee AJ, Roodman GD. Advances in supportive care for multiple myeloma.J Natl Compr Canc Netw. 2014;12:502-511.
IMWG website. Publications. Available at: http://imwg.myeloma.org/category/imwg-publications/. Accessed July 4, 2018.
Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhasharan K. Herpes zoster risk after 21 specific cancers: population-based case–control study. Br J Cancer. 2017;116:1643-1651.
Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26:4784-4790.
Kamber C, Zimmerli Suter-Riniker F, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant. 2015;50:573-578.
Fukushima T, Sato T, Nakamura T, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012;32:5437-5440.
Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.
Anderson K, Ismaila N, Flynn PJ, et al Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2018;36:812-818.
Colson K. Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer. 2015;23:1431-1445.
Drayson M, et al. Tackling early morbidity and mortality in myeloma (TEAMM): assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients [ASH abstract 903]. Blood. 2017;130.
Kumar S, Anderson KC, Durie B, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-e346.
Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130:963-973.
Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152.
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27-38.
Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621-1634.
Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319-1331.
Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754-766.
San Miguel JF, Hungreia VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol. 2014;15:1195-1206.
Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728-734.
Dimopoulos MA, Goldschmidt H, Niesviszky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327-1337.
van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13-29.
Mateos MV, Moreau P, Berenson JR, et al. Once-weekly versus twice-weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma: results of the randomized phase 3 study A.R.R.O.W. Presented at: 2018 American Society of Clinical Oncology meeting. Chicago, IL. Abstract 8000.
Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16:241-245.
Giralt S, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21:2039-2051.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Joseph Mikhael, MD, MEd, FRCPC

Chief Medical Officer
International Myeloma Foundation
Professor
City of Hope Cancer Center
Los Angeles, California

Disclosures

Disclosure: Joseph Mikhael, MD, MEd, FRCPC, FACP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Sanofi

Dr Mikhael does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Mikhael does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Rafat Abonour, MD

Professor of Pathology & Laboratory Medicine
Medical Director, Bone Marrow Transplant Program
Medical Director, Stem Cell Laboratory
Indiana University School of Medicine
Indianapolis, Indiana

Disclosures

Disclosure: Rafat Abonour, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Takeda Pharmaceuticals North America, Inc.

Dr Abonour does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Abonour does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Thomas Martin, MD

Professor of Clinical Medicine
UCSF Medical Center
San Francisco, California

Disclosures

Disclosure: Thomas Martin, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche
Received grants for clinical research from: Amgen Inc.; Sanofi

Dr Martin does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Martin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Sara Fagerlie, PhD, CHCP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Master Class: Proteasome Inhibitor-Based Therapy

Authors: Rafat Abonour, MD; Thomas Martin, MD; Joseph Mikhael, MD, MEd, FRCPC
CME / ABIM MOC Released: 9/6/2018
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 9/6/2019

Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with multiple myeloma.

The goal of this activity is to increase knowledge and competence for healthcare professionals managing care of patients undergoing treatment with proteasome inhibitor (PI)-based combination therapy for the treatment of multiple myeloma (MM).

Upon completion of this activity, participants will:

Have increased knowledge regarding
- Differentiating PI-based combination treatments for MM
Demonstrate greater confidence in their ability to
- Select optimal PI-based regimens for appropriate patients with MM

Disclosures

Faculty

Joseph Mikhael, MD, MEd, FRCPC

Chief Medical Officer
International Myeloma Foundation
Professor
City of Hope Cancer Center
Los Angeles, California

Disclosures

Disclosure: Joseph Mikhael, MD, MEd, FRCPC, FACP, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Sanofi

Dr Mikhael does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Mikhael does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Rafat Abonour, MD

Professor of Pathology & Laboratory Medicine
Medical Director, Bone Marrow Transplant Program
Medical Director, Stem Cell Laboratory
Indiana University School of Medicine
Indianapolis, Indiana

Disclosures

Disclosure: Rafat Abonour, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Takeda Pharmaceuticals North America, Inc.

Dr Abonour does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Abonour does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Thomas Martin, MD

Professor of Clinical Medicine
UCSF Medical Center
San Francisco, California

Disclosures

Disclosure: Thomas Martin, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche
Received grants for clinical research from: Amgen Inc.; Sanofi

Dr Martin does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Martin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Sara Fagerlie, PhD, CHCP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Master Class: Proteasome Inhibitor-Based Therapy

Authors: Rafat Abonour, MD; Thomas Martin, MD; Joseph Mikhael, MD, MEd, FRCPCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 9/6/2018

Valid for credit through: 9/6/2019

processing....

Abbreviations

Abs = antibodies
ADCC = antibody-dependent cell cytotoxicity
AE = adverse event
AKT = protein kinase B
ASCT = autologous stem cell transplant
β₂m = β₂microglobulin
BM = bone marrow
BP = blood pressure
Car = carfilzomib
CAR-T = chimeric antigen receptor T cell
CBC = complete blood cell count
cFLIP = FADD-like inhibitory protein
CHF = congestive heart failure
CLL = chronic lymphocytic leukemia
CR = complete response
CRAB = hypercalcemia, renal failure, anemia, and bone lesions
CrCL = creatinine clearance
CT = computed tomography
CyBorD = cyclophosphamide, bortezomib, dexamethasone
dara = daratumumab
del = deletion
dex = dexamethasone
DOAC = direct oral anticoagulant
DRd = daratumumab, lenalidomide, dexamethasone
DVd = daratumumab, bortezomib, dexamethasone
ECOG = Eastern Cooperative Oncology Group
ERd = elotuzumab, lenalidomide, dexamethasone
FADD = FAS associated death domain
FDA = US Food and Drug Administration
FISH = fluorescent in situ hybridization
FLC = free light chain
GI = gastrointestinal
HDAC = histone deacetylase
HR = hazard ratio
HSV = herpes simplex virus
IFM = Intergroupe Francophone du Myélome
IgA = immunoglobulin A
IGF1 = insulin-like growth factor1
IgG = immunoglobulin G
IMWG = International Myeloma Working Group
IRd = ixazomib, lenalidomide, dexamethasone
ISS = International Staging System
IV = intravenous
JAK = Janus activating kinase
Kd = carfilzomib and dexamethasone
KRd = carfilzomib, lenalidomide, dexamethasone
LDH = lactate dehydrogenase
Len = lenalidomide
LMWH = low molecular weight heparin
MAPK = mitogen-activated protein kinase
MEK = mitogen/extracellular signal-regulated kinase
MM = multiple myeloma
MRD = minimal residual disease
MRI = magnetic resonance imaging
NFkB = nuclear factor kB
NK = natural killer
NR = not reached
obs = observation
ONJ = osteonecrosis of the jaw
OR = odds ratio
ORR = overall response rate
OS = overall survival
PanoVD = panobinostat, bortezomib, dexamethasone
PBSC = peripheral blood stem cell
PD = progressive disease
PET = positron emission tomography
PFS = progression-free survival
PI = proteasome inhibitor
PN = peripheral neuropathy
PO = oral
QoL = quality of life
R = randomization
Rd = lenalidomide, dexamethasone
R-ISS = Revised International Staging System
R/R = relapsed/refractory
R/R MM = relapsed/refractory multiple myeloma
SC = subcutaneous
SCT = stem cell transplant
SDF = stromal-derived factor
sFLC = serum free light chain
SHP1 = small heterodimer partner
SLAMF7 = signaling lymphocytic activation molecule F7
SMM = smoldering multiple myeloma
SPEP = serum protein electrophoresis
SPD = sum of the products of diameters
SPM = second primary malignancy
STAT = signal transducers and activators of transcription
SWOG = Southwest Oncology Group
t = translocation
TLS = tumor lysis syndrome
TNF = tumor necrosis factor
UIFE = urine immunofixation electrophoresis
ULN = upper limit of normal
UPEP = urine protein electrophoresis
VCAM1 = vascular cell adhesion molecule 1
VD = bortezomib, dexamethasoneVEGF = vascular endothelial growth factor
VGPR = very good partial response
VLA1 = very late activating antigen
VMP = bortezomib, melphalan, prednisone
VRd = bortezomib, lenalidomide, dexamethasone
VZV = varicella-zoster virusWB LDCT = whole‐body low dose computed tomography
WB MRI = whole-body magnetic resonance imaging

« Return to: Master Class: Proteasome Inhibitor-Based Therapy

CME / ABIM MOC Information Download Slides

PDF Downloads

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Joseph Mikhael, MD, MEd, FRCPC

Rafat Abonour, MD

Thomas Martin, MD

Editor

Sara Fagerlie, PhD, CHCP

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Master Class: Proteasome Inhibitor-Based Therapy

Target Audience and Goal Statement

Disclosures

Faculty

Joseph Mikhael, MD, MEd, FRCPC

Rafat Abonour, MD

Thomas Martin, MD

Editor

Sara Fagerlie, PhD, CHCP

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Master Class: Proteasome Inhibitor-Based Therapy

Abbreviations

PDF Downloads